48.36
price down icon1.06%   -0.52
after-market 시간 외 거래: 48.36
loading
전일 마감가:
$48.88
열려 있는:
$47.92
하루 거래량:
1.21M
Relative Volume:
1.41
시가총액:
$3.03B
수익:
$45.48M
순이익/손실:
$169.95M
주가수익비율:
18.46
EPS:
2.62
순현금흐름:
$230.85M
1주 성능:
-7.94%
1개월 성능:
+28.65%
6개월 성능:
+7.47%
1년 성능:
+67.16%
1일 변동 폭
Value
$47.09
$48.80
1주일 범위
Value
$47.09
$53.58
52주 변동 폭
Value
$24.22
$60.60

Protagonist Therapeutics Inc Stock (PTGX) Company Profile

Name
명칭
Protagonist Therapeutics Inc
Name
전화
(510) 474-0170
Name
주소
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Name
직원
0
Name
트위터
Name
다음 수익 날짜
2024-11-04
Name
최신 SEC 제출 서류
Name
PTGX's Discussions on Twitter

PTGX을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
PTGX
Protagonist Therapeutics Inc
48.36 3.03B 45.48M 169.95M 230.85M 2.62
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-12-06 개시 BMO Capital Markets Outperform
2024-12-06 개시 Goldman Neutral
2024-11-05 개시 Wedbush Outperform
2024-09-24 개시 TD Cowen Buy
2024-09-09 개시 Truist Buy
2023-10-30 개시 CapitalOne Overweight
2023-05-25 재개 Jefferies Buy
2022-08-25 개시 JMP Securities Mkt Outperform
2022-02-11 개시 BTIG Research Buy
2021-10-12 업그레이드 JP Morgan Neutral → Overweight
2021-10-11 업그레이드 Northland Capital Market Perform → Outperform
2021-09-20 다운그레이드 JP Morgan Overweight → Neutral
2021-05-24 개시 JMP Securities Mkt Outperform
2021-05-24 개시 Northland Capital Outperform
2021-01-06 개시 JP Morgan Overweight
2020-12-16 개시 Piper Sandler Overweight
2020-09-18 재확인 H.C. Wainwright Buy
2020-07-15 개시 Jefferies Buy
2020-05-18 재확인 H.C. Wainwright Buy
2019-07-08 개시 H.C. Wainwright Buy
2019-05-09 업그레이드 Stifel Hold → Buy
2018-12-06 개시 Nomura Buy
2018-01-29 개시 Stifel Buy
2017-07-21 개시 BTIG Research Buy
모두보기

Protagonist Therapeutics Inc 주식(PTGX)의 최신 뉴스

pulisher
Mar 25, 2025

Wall Street Analysts See a 27.36% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High? - Yahoo Finance

Mar 25, 2025
pulisher
Mar 23, 2025

Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025 - Bluefield Daily Telegraph

Mar 23, 2025
pulisher
Mar 22, 2025

Why Protagonist Therapeutics, Inc. (PTGX) Went Up on Monday - MSN

Mar 22, 2025
pulisher
Mar 21, 2025

Insider Sell: William Waddill Sells 4,000 Shares of Protagonist Therapeutics Inc (PTGX) - GuruFocus

Mar 21, 2025
pulisher
Mar 20, 2025

Protagonist Therapeutics Takeda To Lead Regulatory Strategy For Rusfertide In Polycythemia Vera NDA - MarketScreener

Mar 20, 2025
pulisher
Mar 20, 2025

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. With Losses of $100,000 to Contact the Firm - Business Wire

Mar 20, 2025
pulisher
Mar 19, 2025

Protagonist Therapeutics director Waddill sells $217,000 in stock By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Protagonist Therapeutics director Waddill sells $217,000 in stock - Investing.com

Mar 19, 2025
pulisher
Mar 18, 2025

Analysts Mentions Growth Catalysts for Protagonist Therapeutics (PTGX) — Best Biotech Stock for 2025? - MSN

Mar 18, 2025
pulisher
Mar 18, 2025

These 10 biotech companies are changing how we discover new drugs and treat complex diseases - Fast Company

Mar 18, 2025
pulisher
Mar 18, 2025

Fast Company Ranks Protagonist Among Elite Biotech Innovators: 2 FDA Filings Coming - StockTitan

Mar 18, 2025
pulisher
Mar 15, 2025

Is Protagonist Therapeutics, Inc. (PTGX) the Best Healthcare Stock For Long-Term Investment? - Insider Monkey

Mar 15, 2025
pulisher
Mar 15, 2025

Protagonist Therapeutics CFO Ali Asif sells $1.46 million in stock By Investing.com - Investing.com South Africa

Mar 15, 2025
pulisher
Mar 15, 2025

Protagonist Therapeutics’ chief medical officer sells $1.7 million in stock By Investing.com - Investing.com Canada

Mar 15, 2025
pulisher
Mar 14, 2025

Protagonist Therapeutics CFO Ali Asif sells $1.46 million in stock - Investing.com India

Mar 14, 2025
pulisher
Mar 14, 2025

Protagonist Therapeutics’ chief medical officer sells $1.7 million in stock - Investing.com

Mar 14, 2025
pulisher
Mar 14, 2025

Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $76.00 - Defense World

Mar 14, 2025
pulisher
Mar 14, 2025

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Purchased by Victory Capital Management Inc. - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out - MSN

Mar 13, 2025
pulisher
Mar 13, 2025

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Acquired by Bank of New York Mellon Corp - Defense World

Mar 13, 2025
pulisher
Mar 13, 2025

Protagonist Therapeutics’ SWOT analysis: promising pipeline drives stock outlook By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 12, 2025

Protagonist Therapeutics’ SWOT analysis: promising pipeline drives stock outlook - Investing.com

Mar 12, 2025
pulisher
Mar 12, 2025

Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's Why - Yahoo Finance

Mar 12, 2025
pulisher
Mar 12, 2025

Learn to Evaluate (PTGX) using the Charts - Stock Traders Daily

Mar 12, 2025
pulisher
Mar 12, 2025

Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $72.00 at BMO Capital Markets - Defense World

Mar 12, 2025
pulisher
Mar 12, 2025

Protagonist Therapeutics (NASDAQ:PTGX) Hits New 1-Year High on Analyst Upgrade - Defense World

Mar 12, 2025
pulisher
Mar 11, 2025

Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It (NASDAQ:PTGX) - Seeking Alpha

Mar 11, 2025
pulisher
Mar 11, 2025

Wedbush Adjusts Protagonist Therapeutics Price Target to $70 From $58, Maintains Outperform Rating - Marketscreener.com

Mar 11, 2025
pulisher
Mar 11, 2025

Protagonist Therapeutics Soars as Icotrokinra Drives Breakthroug - GuruFocus.com

Mar 11, 2025
pulisher
Mar 11, 2025

Protagonist Therapeutics price target raised to $76 from $60 at Truist - TipRanks

Mar 11, 2025
pulisher
Mar 11, 2025

Protagonist Therapeutics Soars as Icotrokinra Drives Breakthrough Success - Yahoo Finance UK

Mar 11, 2025
pulisher
Mar 11, 2025

Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga

Mar 11, 2025
pulisher
Mar 11, 2025

Protagonist Therapeutics price target raised to $72 from $62 at BMO Capital - TipRanks

Mar 11, 2025
pulisher
Mar 11, 2025

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Shares Climb 44% But Its Business Is Yet to Catch Up - Simply Wall St

Mar 11, 2025
pulisher
Mar 11, 2025

Protagonist Therapeutics price target raised to $80 from $54 at H.C. Wainwright - TipRanks

Mar 11, 2025
pulisher
Mar 11, 2025

Protagonist Therapeutics Gets IBD Stock Rating Upgrade - Investor's Business Daily

Mar 11, 2025
pulisher
Mar 11, 2025

10 Firms Buck Market Bloodbath on Monday - Insider Monkey

Mar 11, 2025
pulisher
Mar 11, 2025

Protagonist Therapeutics’ (PTGX) Buy Rating Reaffirmed at HC Wainwright - Defense World

Mar 11, 2025
pulisher
Mar 10, 2025

PTGX stock soars to 52-week high, reaching $50.18 By Investing.com - Investing.com Australia

Mar 10, 2025
pulisher
Mar 10, 2025

BTIG maintains Buy on Protagonist Therapeutics, target at $73 By Investing.com - Investing.com Canada

Mar 10, 2025

Protagonist Therapeutics Inc (PTGX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
자본화:     |  볼륨(24시간):